UNSPSC 51413302: Gemeprost

This classification denotes a prostaglandin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 45KZB1FOLS. European Medicines Agency schedules Gemeprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07893MIG. Gemeprost generally arises in the molecular formula C23H38O5.

UNSPSC 51413302 Gemeprost, a Commodity code, encompasses advanced life support medications and pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing initiatives. State and local buyers under this code are primarily municipal fire and emergency services departments, state health and human services agencies, and cooperative purchasing alliances representing multiple state and local jurisdictions. The actual procurement spans specific generic and branded medications used in acute care settings—epinephrine, labetalol, adenosine, diltiazem, and other medications distributed through authorized wholesalers—as well as broader pharmaceutical sourcing arrangements that include gemeprost and other specialized products. Vendors typically supply through established pharmaceutical wholesalers under direct-to-manufacturer or direct-contract arrangements, with delivery requirements ranging from immediate (within ten calendar days) to longer-term framework agreements supporting statewide or multistate distribution.

Recent activity shows concentration in Florida, Texas, and Minnesota. The City of Tampa Fire Rescue issued IFB No. 26P00188 in April 2026 for Advanced Life Support Medications with a $40,000 estimated contract value and April 8, 2026 response deadline, requiring vendors to supply four medication line items with nine-month minimum expiration dates and firm pricing including freight to Tampa. The Texas Health and Human Services Commission posted RFI No. HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer pharmacy programs, signaling early-stage procurement planning without immediate award timelines. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP No. S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, emphasizing price competitiveness (75 percent evaluation weight) and compliance with cGMP and DSCSA standards. Cooperative purchasing vehicles dominate the landscape, with MMCAP extending benefits across Minnesota and Oregon; individual municipalities and state agencies pursue direct procurement through sealed-bid and RFP mechanisms.